Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information
This activity will review the latest PK recommendations for Factor VIII and IX replacement and how to use and interpret PK parameters to assess treatment plans.
Choose from the criteria below to find an activity that fits you best.
|A product of the National Association of Specialty Pharmacy's (NASP) Center for Specialty Pharmacy Education (CSPE)|
NOTE: If you attended the live CE activity titled "A Perspective on Pharmacy Benefit Management: The Rise and Role of Specialty Pharmacy" that was held on September 27, 2016 during the NASP Annual Meeting & Expo in Washington, DC AND received CE credit (i.e. a pharmacist CE statement with ACPE Universal Activity Number 0221-9999-16-180-L04-P), you are ineligible to also receive CE credit for this home-study activity.
This is a featured CE activity on the Center for Specialty Pharmacy Education (CSPE) website. CSPE is the educational hub of the National Association of Specialty Pharmacy (NASP). This activity was originally presented during the National Association of Specialty Pharmacy Fourth Annual Meeting & Expo held in Washington, DC. This Keynote session provided a unique perspective on aspects of pharmacy benefit management, including changing market dynamics, barriers for usage and adherence, and tools to manage trends.
The target audience for this activity is pharmacists. Upon completion of this activity, participants will be able to:
Marty Mattei, PharmD
VP, Clinical Product Innovation
MedImpact Healthcare Systems, Inc.
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Marty Mattei does not have any relevant commercial or financial relationships to disclose.
The opinions expressed in this activity should not be construed as those of the CE provider. The information and views are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the use of drugs for unlabeled indications. Use of drugs outside of labeling should be considered experimental and participants are advised to consult prescribing information and professional literature.
Release Date: 12-01-2016
Expiration Date: 6-01-2018
This CE activity is jointly provided by ProCE, Inc. and NASP. ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-16-341-H04-P has been assigned to this knowledge-based home-study CE activity (initial release date 12-01-16). This activity is approved for 0.75 contact hour (0.075 CEU) in states that recognize ACPE providers. Completion of the evaluation is required to receive CE credit. No partial credit will be given.
No external support has been received for this activity.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.